Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01967940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01967940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
October 25, 2013
Completion date
July 31, 2017
Enrollment
55 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

acquired immunodeficiency syndrome, hiv, hiv infections